嗜睡症治療市場－全球產業規模、佔有率、趨勢、機會、預測：依治療方法、產品、地區和競爭格局分類，2021-2031年

全球嗜睡症治療市場預計將從 2025 年的 34.2 億美元成長到 2031 年的 50.9 億美元，複合年成長率為 6.85%。

這些療法涉及藥物干預，旨在治療因大腦無法調節睡眠-覺醒週期而導致的慢性神經系統疾病，主要針對白天過度嗜睡、猝倒和夜間睡眠障礙等症狀。該領域的發展主要得益於睡眠障礙在全球範圍內日益普遍，以及診斷技術的進步，使得醫療專業人員能夠早期發現疾病。此外，基於機制的治療方法開發和支持孤兒藥的法律規範為產業擴張奠定了堅實的基礎，使其發展軌跡不受市場短期波動的影響。

儘管存在這些積極跡象，但市場仍面臨與複雜診斷流程相關的重大障礙，這往往導致治療啟動時間大幅延遲。根據2023年睡眠研究協會的數據，發作性睡病影響著大約每10萬人口中的37.7人。這項統計數據凸顯了由於疾病的罕見性和漏診率高，患者數量有限所帶來的困境。再加上特效藥物的高昂費用，這些因素都對市場的快速擴張構成了重大阻礙。

市場促進因素

隨著新療法研發管線的拓展和新一代藥物的核准，嗜睡症治療市場格局正發生根本性的重塑。製藥公司正從廣泛緩解症狀轉向針對潛在病理學因素的標靶治療，尤其關注Orexin訊號通路和組織胺調節。這種轉變體現在緩釋製劑日益成長的商業性價值上，緩釋製劑顯著減輕了患者的用藥負擔，而這些先進治療方法的迅速普及也凸顯了市場對依從性更佳治療方法的強勁需求。例如，Abadel Pharmaceuticals在其2024年8月的財報中宣布，其新推出的治療藥物Lumryz第二季淨銷售額達到4,150萬美元，顯示臨床療效和給藥便利性是推動銷售的主要因素。

同時，優惠的報銷方案和患者准入計劃的推出，正成為有效將已確診患者轉化為接受治療患者的關鍵促進因素。生物製藥公司認知到未治療睡眠障礙的長期經濟影響，正利用支持服務來確保藥物的永續可及性。根據Jazz Pharmaceuticals於2024年2月發布的2023年全年財報，第四季接受Xywav治療的患者平均人數增至約12,300人。用戶群的擴大凸顯了透過改善病患准入所取得的商業性成功，該產品系列2023年的年度淨銷售額達到12.7億美元，也直接支撐了整個產業的整體估值。

市場挑戰

與發作性睡病相關的複雜診斷過程是全球治療市場發展的主要障礙，人為地限制了目標患者群體。白天過度嗜睡等症狀常被全科醫生誤診為憂鬱症、失眠或生活方式問題的徵兆，而未被識別為特定的神經系統疾病。這種缺乏準確臨床診斷的情況導致治療路徑支離破碎，患者往往在接受專業睡眠藥物治療前經歷多年的無效治療。因此，製藥公司面臨的市場範圍顯著縮小，有效的治療方法無法惠及那些未被診斷或誤診的患者。

這種診斷缺口直接給依賴處方箋量來收回研發成本的藥物研發者帶來了高風險，並有效地限制了他們的收入潛力。患者識別效率低下導致市場規模遠小於疾病的實際盛行率。根據嗜睡症網路對2025年的預測，約有50%的嗜睡症患者將無法確診。這種嚴重的漏診使得商業市場遠遠未達到其真正的潛力，直接阻礙了擴充性，並抑制了整個產業的擴張。

市場趨勢

市場上的一項重大進展是選擇性Orexin受體促效劑的出現。這使得治療重點從緩解一般症狀轉向標靶化疾病的潛在病理生理機制。與非選擇性調節中樞神經系統活動的傳統興奮劑不同，這些新型候選藥物旨在直接刺激Orexin受體，從而解決導致睡眠-覺醒節律紊亂的特定神經肽缺乏問題。這種以機制為基礎的治療方法因其能夠恢復自然覺醒狀態而非僅僅掩蓋困倦感，正迅速獲得臨床療效。例如，武田製藥公司於2024年6月報告稱，其在研口服Orexin受體2促效劑TAK-861在安慰劑對照試驗中，在覺醒維持測試（MWT）中顯示出統計學意義上的顯著改善（p < 0.001）。

同時，隨著低濫用風險、未分類藥物療法的研發不斷推進，以克服與管制藥物相關的取得限制，競爭格局正在重塑。儘管目前的標準療法通常由於監管規定而需要複雜的風險評估和緩解策略（REMS），但新一代藥物已證實療效顯著，且無需此類繁瑣流程，從而有助於提高患者用藥可及性並簡化處方通訊協定。 Axsome Therapeutics 公司的 AXS-12 等新型去甲腎上腺素再回收抑制劑的進展便是這一趨勢的例證。根據 2024 年 11 月發布的新聞稿，III 期 ENCORE 試驗表明，長期使用該臨床實驗藥物治療六個月後，平均每週猝倒發作次數減少了 77%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球嗜睡症治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療方法（伴隨猝倒的嗜睡症、不伴隨猝倒的嗜睡症、次發性嗜睡症）
  • 副產物（中樞神經系統興奮劑、羥考酮鈉、選擇性血清素再回收抑制劑、三環抗憂鬱藥物、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美嗜睡症治療藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲嗜睡症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區嗜睡症治療藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲嗜睡症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲嗜睡症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球嗜睡症治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Teva Pharmaceutical Industries Ltd.
• Jazz Pharmaceuticals, Inc.
• Harmony Biosciences
• Novartis AG
• Rhodes Pharmaceuticals LP
• Janssen Global Services, LLC
• Eli Lilly and Company

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Narcolepsy Therapeutics Market is projected to expand from a valuation of USD 3.42 Billion in 2025 to USD 5.09 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 6.85%. These therapeutics encompass pharmacological interventions aimed at managing a chronic neurological disorder defined by the brain's inability to regulate sleep-wake cycles, targeting symptoms like excessive daytime sleepiness, cataplexy, and disrupted nocturnal sleep. Growth in this sector is fundamentally driven by the increasing global prevalence of sleep disorders and advancements in diagnostic capabilities that facilitate earlier detection by medical professionals. Additionally, the development of mechanism-based therapies and regulatory frameworks supporting orphan drugs provide a solid foundation for industry expansion, establishing a trajectory distinct from temporary market fluctuations.

Despite these positive indicators, the market faces significant hurdles related to the complex diagnostic process, often causing substantial delays in treatment initiation. Data from the Sleep Research Society in 2023 indicates that narcolepsy affects approximately 37.7 individuals per 100,000 inhabitants. This statistic highlights the difficulty of a limited addressable patient population resulting from the condition's rarity and frequent underdiagnosis. When combined with the high expense of specialized medications, these factors create formidable barriers to rapid market scalability.

Market Driver

The market landscape for narcolepsy treatments is being fundamentally reshaped by the expansion of novel therapeutic pipelines and the approval of next-generation drugs. Pharmaceutical developers are strategically pivoting away from broad symptomatic relief toward targeted interventions that address underlying pathophysiologies, specifically focusing on orexin signaling pathways and histamine modulation. This shift is highlighted by the commercial prioritization of extended-release formulations, which significantly alleviate the dosing burden for patients; the rapid adoption of these advanced therapies confirms strong demand for treatments with better adherence profiles. For instance, Avadel Pharmaceuticals reported in their August 2024 financial results that net product revenue for LUMRYZ, their newly launched treatment, reached $41.5 million for the second quarter, demonstrating that clinical efficacy paired with dosing convenience is a major catalyst for revenue.

Simultaneously, the implementation of favorable reimbursement schemes and patient access programs acts as a critical driver by effectively converting the diagnosed population into treated patients. Recognizing the long-term economic impact of untreated sleep disorders, biopharmaceutical companies are utilizing support services to ensure sustainable medication access. According to Jazz Pharmaceuticals' report in February 2024 regarding full-year 2023 results, the average number of active patients treated with Xywav increased to approximately 12,300 in the fourth quarter. This growth in the user base directly supports substantial sector valuation, as evidenced by the $1.27 billion in annual net product sales for this franchise in 2023, underscoring the commercial viability achieved through improved patient access.

Market Challenge

The intricate diagnostic journey involved in identifying narcolepsy serves as a primary obstacle to the global therapeutics market by artificially constraining the addressable patient base. Symptoms such as excessive daytime sleepiness are often mischaracterized by general practitioners as signs of depression, insomnia, or lifestyle issues rather than a specific neurological condition. This lack of precise clinical identification creates a fragmented care pathway where patients frequently endure years of ineffective management before receiving specialized sleep care, thereby presenting pharmaceutical companies with a severely restricted market where effective therapies cannot reach unidentified or misdiagnosed individuals.

This diagnostic gap directly creates a high-risk environment for drug developers who rely on prescription volume to recoup research and development costs, effectively limiting revenue potential. The inefficiency in locating patients ensures the market size remains disproportionately small compared to the actual prevalence of the disease. According to estimates from the Narcolepsy Network in 2025, approximately 50 percent of individuals affected by this condition remain undiagnosed. This significant rate of underdiagnosis keeps the commercial market far below its true capacity, directly hampering scalability and impeding broader industry expansion.

Market Trends

A pivotal advancement in the market is the emergence of selective orexin receptor agonists, which shifts therapeutic focus from general symptomatic relief to targeting the disease's root pathophysiology. In contrast to traditional stimulants that non-selectively modulate central nervous system activity, these novel pipeline candidates are engineered to directly stimulate orexin receptors, addressing the specific neuropeptide deficiency responsible for sleep-wake instability. This mechanism-driven approach is gaining rapid clinical validation for its potential to restore natural wakefulness rather than merely masking sleepiness; for example, Takeda reported in June 2024 that their investigational oral orexin receptor 2 agonist, TAK-861, demonstrated statistically significant improvement in the Maintenance of Wakefulness Test with a p-value of less than 0.001 compared to placebo.

Concurrently, the competitive landscape is being reshaped by the development of non-scheduled therapeutics designed with lower abuse potential to overcome the restrictive access barriers linked to controlled substances. While current standard-of-care treatments often necessitate complex Risk Evaluation and Mitigation Strategies (REMS) due to their regulatory scheduling, next-generation agents are showing robust efficacy without these burdens, thereby facilitating broader patient access and simplifying prescribing protocols. This trend is illustrated by the progress of novel norepinephrine reuptake inhibitors, such as Axsome Therapeutics' AXS-12; according to a November 2024 press release, the Phase 3 ENCORE trial showed that long-term treatment with this investigational agent resulted in a 77 percent reduction in mean weekly cataplexy attacks over six months.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Jazz Pharmaceuticals, Inc.
• Harmony Biosciences
• Novartis AG
• Rhodes Pharmaceuticals L.P.
• Janssen Global Services, LLC
• Eli Lilly and Company

Report Scope

In this report, the Global Narcolepsy Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Narcolepsy Therapeutics Market, By Treatment

• Narcolepsy with Cataplexy
• Narcolepsy Without Cataplexy
• Secondary Narcolepsy

Narcolepsy Therapeutics Market, By Product

• Central Nervous System Stimulants
• Sodium Oxybate
• Selective Serotonin Reuptake Inhibitor
• Tricyclic Antidepressants
• Others

Narcolepsy Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Narcolepsy Therapeutics Market.

Available Customizations:

Global Narcolepsy Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Narcolepsy Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Narcolepsy with Cataplexy, Narcolepsy Without Cataplexy, Secondary Narcolepsy)
  • 5.2.2. By Product (Central Nervous System Stimulants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Narcolepsy Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Product
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Narcolepsy Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Product
  • 6.3.2. Canada Narcolepsy Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Product
  • 6.3.3. Mexico Narcolepsy Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Product

7. Europe Narcolepsy Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Product
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Narcolepsy Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Product
  • 7.3.2. France Narcolepsy Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Product
  • 7.3.3. United Kingdom Narcolepsy Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Product
  • 7.3.4. Italy Narcolepsy Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Product
  • 7.3.5. Spain Narcolepsy Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Product

8. Asia Pacific Narcolepsy Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Product
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Narcolepsy Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Product
  • 8.3.2. India Narcolepsy Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Product
  • 8.3.3. Japan Narcolepsy Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Product
  • 8.3.4. South Korea Narcolepsy Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Product
  • 8.3.5. Australia Narcolepsy Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Product

9. Middle East & Africa Narcolepsy Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Product
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Narcolepsy Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Product
  • 9.3.2. UAE Narcolepsy Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Product
  • 9.3.3. South Africa Narcolepsy Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Product

10. South America Narcolepsy Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Product
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Narcolepsy Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Product
  • 10.3.2. Colombia Narcolepsy Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Product
  • 10.3.3. Argentina Narcolepsy Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Product

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Narcolepsy Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Teva Pharmaceutical Industries Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Jazz Pharmaceuticals, Inc.
• 15.3. Harmony Biosciences
• 15.4. Novartis AG
• 15.5. Rhodes Pharmaceuticals L.P.
• 15.6. Janssen Global Services, LLC
• 15.7. Eli Lilly and Company

16. Strategic Recommendations

17. About Us & Disclaimer